Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | -4.02% | -6.70% | -44.52% |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Apr. 11 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
Financials (USD)
Sales 2024 * | 28.05M | Sales 2025 * | 72.09M | Capitalization | 41.44M |
---|---|---|---|---|---|
Net income 2024 * | -1M | Net income 2025 * | 39M | EV / Sales 2024 * | 1.48 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.57 x |
P/E ratio 2024 * |
250
x | P/E ratio 2025 * |
0.94
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.89% |
Latest transcript on Ocuphire Pharma, Inc.
1 day | -4.02% | ||
1 week | -6.70% | ||
Current month | -16.92% | ||
1 month | -13.47% | ||
3 months | -39.71% | ||
6 months | -47.32% | ||
Current year | -44.52% |
Managers | Title | Age | Since |
---|---|---|---|
George Magrath
CEO | Chief Executive Officer | 40 | Oct. 31 |
Nirav Jhaveri
DFI | Director of Finance/CFO | 46 | Feb. 13 |
Barbara Withers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 20-10-31 |
James Manuso
BRD | Director/Board Member | 75 | 18-12-31 |
Susan Benton
BRD | Director/Board Member | 59 | 20-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 1.67 | -4.02% | 239,627 |
24-04-17 | 1.74 | 0.00% | 92,408 |
24-04-16 | 1.74 | -1.14% | 113,769 |
24-04-15 | 1.76 | -4.35% | 199,447 |
24-04-12 | 1.84 | +2.79% | 470,172 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.52% | 41.44M | |
+27.97% | 672B | |
+23.58% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.96% | 211B | |
-0.41% | 203B | |
-10.02% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- OCUP Stock